Exchange: HKSE Sector: Healthcare Industry: Biotechnology
-1.10% HKD0.450
America/New_York / 3 mai 2024 @ 03:52
FUNDAMENTALS | |
---|---|
MarketCap: | 191.18 mill |
EPS: | -0.960 |
P/E: | -0.470 |
Earnings Date: | Aug 21, 2024 |
SharesOutstanding: | 424.84 mill |
Avg Daily Volume: | 0.0442 mill |
RATING 2024-05-03 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | n/a | n/a | |||
Ebit | n/a | n/a | n/a | |||
Asset | n/a | n/a | n/a | |||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.470 | sector: PE 34.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.470 | industry: PE 35.62 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
HKD 0.423 - 0.477 ( +/- 6.00%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | HKD0.450 (-1.10% ) |
Volume | 0.110 mill |
Avg. Vol. | 0.0442 mill |
% of Avg. Vol | 248.76 % |
Signal 1: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.